Tests BGB-11417 alone or with azacitidine in myeloid blood cancers
Tests BGB-11417, alone or with azacitidine, in adults with acute myeloid leukemia or MDS.
Key facts
- Who runs it
- BeOne Medicines
- Where
- GangnamGu and SeodaemunGu, South KoreaSee the 2 sitesAlso in 9 other countries, 45 sites
- Trial code
- NCT04771130
- EU 2023-508881-14-00
- EudraCT 2021-003285-12
- U1111-1306-8570
- Registry title
- A Study of BGB-11417 in Participants With Myeloid Malignancies
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 260 people, planned
- Started
- 24 May 2021
- Expected to end
- 31 Aug 2028
- Type of study
- Interventional, 4 groups
- Treatments tested
- BGB-11417
- Azacitidine
- Posaconazole
- Record updated
- 14 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) or MDS/myeloproliferative neoplasm (MDS/MPN), confirmed by 2016 World Health Organization criteria.
- Age
- 18 years and older
- Sex
- All sexes can join.
- Disease stage
- AML (not acute promyelocytic leukemia), MDS or MDS/MPN. Performance status (Eastern Cooperative Oncology Group) of 0 to 2 and life expectancy of more than 12 weeks.
- Earlier treatment
- People who had earlier treatment with a B-cell lymphoma-2 inhibitor cannot join.
- Biomarker or test result
- Creatinine clearance of at least 50 mL/min (30 to 49 mL/min in the unfit AML group) and adequate liver function.
Main reasons for not taking part
- Acute promyelocytic leukemia
- Earlier cancer, with a few exceptions (for example treated with full intent and no return within 2 years)
- Earlier myeloproliferative neoplasm such as myelofibrosis, essential thrombocytosis, polycythemia vera or chronic myelogenous leukemia
- Earlier treatment with a B-cell lymphoma-2 inhibitor
- Known leukemia in the central nervous system
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Confirmed diagnosis of one of the following by 2016 World Health Organization criteria:; AML, nonacute promyelocytic leukemia; MDS; MDS/MPN
- Eastern Cooperative Oncology Group performance status of 0 to 2
- Adequate organ function defined as:; Creatinine clearance ≥ 50 milliliters/minute (mL/min) (or between 30 and 49 mL/min in unfit AML cohort); Adequate liver function
- Life expectancy of > 12 weeks
- Ability to comply with the requirements of the study
Who cannot take part
- Prior therapy with a B-cell lymphoma-2 inhibitor
- History of prior malignancy, with the exception of either a history of MDS or MDS/MPN that has transformed to AML, or other prior malignancy that was treated with a full curative intent and no evidence of recurrence within the past 2 years (eg, localized skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast, or localized Gleason score ≤ 6 prostate cancer)
- A diagnosis of acute promyelocytic leukemia
- Antecedent MPN including myelofibrosis, essential thrombocytosis, polycythemia vera, or chronic myelogenous leukemia with or without BCR-ABL1 translocation and AML with BCR-ABL1 translocation
- Known central nervous system involvement by leukemia; Note: Other protocol defined Inclusion/Exclusion criteria may apply
Where in South Korea
Also in 9 other countries, 45 sites
- Samsung Medical CenterGangnamGu, South KoreaContact: Study DirectorTaking people
- Severance Hospital Yonsei University Health SystemSeodaemunGu, South KoreaContact: Study DirectorTaking people
About the trial
What the trial wants to find out
The study will determine the safety, tolerability, recommended Phase 2 dose (RP2D) and preliminary efficacy of BGB-11417 as monotherapy and in combination with azacitidine in participants with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)or MDS/myeloproliferative neoplasm (MPN) .
The 4 groups in the trial
- Parts 1 and 2: AML CohortsTreatment being tested
Participants with AML will receive BGB-11417 and azacitidine on a 28-day cycle.
Treatment: BGB-11417 and Azacitidine
- Parts 1 and 2: MDS CohortsTreatment being tested
Participants with MDS will receive BGB-11417 and azacitidine on a 28-day cycle.
Treatment: Azacitidine and BGB-11417
- Part 3: AML and MDS CohortsTreatment being tested
Participants with AML and MDS will receive BGB-11417 and azacitidine on a 28-day cycle. A subset of the participants will receive a modified second cycle of treatment to explore drug-drug interactions (DDI) with posaconazole.
Treatment: BGB-11417, Azacitidine, and Posaconazole
- Part 3: AML and MDS CohortTreatment being tested
Participants with MDS and R/R AML (China only) will receive BGB-11417 on a 28-day cycle.
Treatment: BGB-11417
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies
- Plain-language title
- Tests BGB-11417 alone or with azacitidine in myeloid blood cancersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 14 September 2026